Faraj, K., Mirza, S. (2021). Immunohistochemical Application of GATA 3 in Differentiating Urothelial Cancer from Prostatic Cancer. A Clinicopathological Study. Alustath, 21(4), 412-419. doi: 10.52573/ipmj.2021.176987
Khamaeel Khaleel Faraj; Sazan Abdulwahab Mirza. "Immunohistochemical Application of GATA 3 in Differentiating Urothelial Cancer from Prostatic Cancer. A Clinicopathological Study". Alustath, 21, 4, 2021, 412-419. doi: 10.52573/ipmj.2021.176987
Faraj, K., Mirza, S. (2021). 'Immunohistochemical Application of GATA 3 in Differentiating Urothelial Cancer from Prostatic Cancer. A Clinicopathological Study', Alustath, 21(4), pp. 412-419. doi: 10.52573/ipmj.2021.176987
Faraj, K., Mirza, S. Immunohistochemical Application of GATA 3 in Differentiating Urothelial Cancer from Prostatic Cancer. A Clinicopathological Study. Alustath, 2021; 21(4): 412-419. doi: 10.52573/ipmj.2021.176987

Immunohistochemical Application of GATA 3 in Differentiating Urothelial Cancer from Prostatic Cancer. A Clinicopathological Study

Iraqi Postgraduate Medical Journal
Article 7, Volume 21, Issue 4, October 2022, Pages 412-419    PDF (1.98 M)
Document Type: Research Paper
DOI: 10.52573/ipmj.2021.176987
Authors
Khamaeel Khaleel Faraj; Sazan Abdulwahab Mirza*
Department of Pathology, College of Medicine/ University of Baghdad, Baghdad, Iraq.
Abstract
BACKGROUND:
Urothelial carcinoma and prostatic adenocarcinoma are the most common tumors of genitourinary system. Both can demonstrate a broad histology or present as undifferentiated carcinoma that made the distinction of which is the primary source very difficult. In indeterminate tumor morphology,    the immunohistochemical markers will assist the pathologists to avoid misinterpretation.
AIM OF THE STUDY:
To assess immunohistochemical expression of GATA3 in urothelial and prostatic adenocarcinoma with correlation to different clinicopathological parameters.
MATERIALS AND METHODS:
This retrospective study was done on formalin-fixed paraffin embedded tissue blocks from 20 urothelial CA and 20 prostatic adenocarcinoma cases. GATA3 was used and semi-quantitatively scored.
RESULTS:
90% of urothelial CA cases were GATA3 positive with 75% strong expression. While 85% of prostatic CA cases were GATA3 negative, there was no significant correlation between GATA3 expression and clinicopathological parameters except for gender in urothelial CA.
CONCLUSION:
GATA3 has a potential role to confirm the urothelial origin of the tumor in comparison to prostatic carcinoma. There was no significant correlation between GATA3 expression in urothelial carcinoma and  prostatic carcinoma cases and clinicopathological parameters except for gender in the first.
 
Keywords
GATA3; urothelial carcinoma; prostatic adenocarcinoma
References
  1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3:524.
  2. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7):737-45.
  3. Reulen RC, Kellen E, Buntinx F, et al. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl. 2008;218:64–78.
  4. Abol-Enein H. Infection: is it a cause of bladder cancer? Scand J Urol Nephrol Suppl. 2008; 218:79–84.
  5. Amin MB, Smith SC, Reuter VE, et al: Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol.2015; 28:612-630.
  6. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal. 2006;6:2617-25.
  7. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Modern Pathology.2009;22:S96– S118.
  8. Iaffaioli RV, Milano A, Caponigro F. Therapy of metastatic bladder cancer. Annals of Oncology. 2007;18 (supplement 6): vi153-vi156.
  9. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer.2003;97:1894–1903. 69
  10. Zhu C, et al. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. The Journal of biological chemistry. 2011; 286:33478–88.
  11. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol.2015;69:428-35.
  12. Reisenbichler, E., 2020. GATA3. [online] Pathologyoutlines.com. Available at: [Accessed 30 January 2021]
  13. Peter A. Humphrey, Holger Moch, Antonio L. Cubilla, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male 73 Genital Organs-Part B: Prostate and Bladder Tumours. EUROPEAN UROLOGY. 2016; 70:106-19.  
  14. Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, Singh V, Sinha RJ. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol 2019;62:244- 50.
  15. Markk M, Peter A, Zenfeng wang, GATA3- a multispecific but potentially useful marker in surgical pathology . A systematic analysis of 2500 epithelial and non epithelial tumors. Am J surg . pathol. 2014 38:13-22.
  16. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36:1472-76.
  17. Oh WJ, Chung AM, Kim JS, et al. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. J Pathol Transl Med. 2016;50:345-54.
  18. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
  19. Clark BZ, Beriwal S, Dabbs DJ, et al. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol. 2014;142:64-71.
  20. Abdullah, W. H., Kerbel, H. A., & Al Husseini, R. F. (2018). APPLYING GATA3 IN DIFFERENTIATING UROTHELIAL CARCINOMA FROM PROSTATIC ADENOCARCINOMA: AN IMMUNOHISTOCHEMICAL STUDY. Asian Journal of Pharmaceutical and Clinical Research,11:292. doi:10.22159/ajpcr.2018.v11i12.28232.
  21. Helmy, Noha A.H.; Khalil, Heba K.M.; Kamel, Nora N.; et al. Role of GATA3, CK7, CK20 and CK14 in distinguishing urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation. Egyptian Journal of Pathology 2015;35:133–38.
  22. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.
  23. Leivo MZ, Elson PJ, Tacha DE, et al. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology. 2016;48:543–49.
  24. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-80.
  25. Naik, M., Rao, B.V., Fonseca, D. et al. GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma. Indian J Surg Oncol(2020). https://doi.org/10.1007/s13193- 019-01026-0
  26. Nahla Abdelfattah Kamel, Eman Abdelzaher, Omar Elgebaly & Shery Abdullah Ibrahim (2019): Reduced expression of GATA3 predicts 84 84progression in non–muscle invasive urothelial carcinoma of the urinary bladder, Journal Histotechnology, DOI: 10.1080/01478885.2019.1667126
  27. McDonald, Timothy M. MD; Epstein, Jonathan I. MD Aberrant GATA3 Staining in Prostatic Adenocarcinoma, The American Journal of Surgical Pathology: August 04, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/PAS.0000000000001557
  28. Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., … Klein, E. A. (2016). A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 69,428–35. doi:10.1016/j.eururo.2015.06.046

 

 

Statistics
Article View: 36
PDF Download: 49


Journal Management System. Powered by ejournalplus.com